Clinical Trial Update: A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating time in range with Afrezza plus basal insulin versus multiple daily injections in Type 2 diabetes treated with insulin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)

Snippet

Sponsor: Diabetes and Glandular Disease Clinic | Conditions: Type 2 Diabetes Treated With Insulin | Phase 4 | Status: UNKNOWN